RE:RE:RE:Pfizer's Trillium & GBT M&A deals not the last Consequently, over the past two years, Pfizer has significantly ramped up its deal-making in an effort to add $25 billion of risk-adjusted revenue by 2030. And as already outline, here are Pfizer's most significant deals over this period:
| COMPANY NAME | PRICE TAG | KEY ASSETS |
| Arena Pharmaceuticals | $6.7 billion | Late-stage ulcerative colitis medication etrasimod |
| Biohaven Pharmaceutical | $11.6 billion | Migraine drug Nurtec ODT/CGRP inhibitor portfolio |
| Global Blood Therapeutics | $5.4 billion | Sickle cell disease drug Oxbryta and other pipeline candidates |
| ReViral | $525 million | Respiratory syncytial virus candidates |
| Trillium Therapeutics | $2.3 billion | CD47 cancer therapies |
And as part of its long term strategy to add $25 Billion of risk adjusted revenue by 2030 Pfizer looks on track for the time being to simply continue snapping up small-to-mid-sized companies in the company's so-called "string of pearls" strategy.
Pfizer's "string of pearls" strategy includes "Bolt-on acquistions" and platform technologies as seen over the past 2 years, and ONCY's Immune Molecule Platform Technology in pelareorep and "bolt-on" appeal would suggest ONCY as a likely "pearl" of a company for another targeted acquisition by Pfizer.